AGATHANGELIDIS, A., Nikos DARZENTAS, A. HADZIDIMITRIOU, X. BROCHET, F. MURRAY, X. YAN, Z. DAVIS, E. VAN GASTEL-MOL, C. TRESOLDI, Ch. CHU, N. CAHILL, V. GIUDICELLI, Boris TICHÝ, L. PEDERSEN, L. FORONI, L. BONELLO, A. JANUS, K. SMEDBY, A. ANAGNOSTOPOULOS, H. MERLE-BERAL, N. LAOUTARIS, G. JULIUSSON, P. DI CELLE, Šárka POSPÍŠILOVÁ, J. JURLANDER, Ch. GEISLER, A. TSAFTARIS, M. LEFRANC, A. LANGERAK, D. OSCIER, N. CHIORAZZI, Ch. BELESSI, F. DAVI, R. ROSENQUIST, P. GHIA and K. STAMATOPOULOS. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Online. Blood. Washington, DC: American Society of Hematology, 2012, vol. 119, No 19, p. 4467-4475. ISSN 0006-4971. Available from: https://dx.doi.org/10.1182/blood-2011-11-393694. [citováno 2024-04-24]
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies
Name in Czech Stereotypní B-buněčných receptorů v jedné třetině chronickou lymfocytární leukemií: molekulární klasifikace s důsledky pro cílených terapií
Authors AGATHANGELIDIS, A. (300 Greece), Nikos DARZENTAS (300 Greece), A. HADZIDIMITRIOU (300 Greece), X. BROCHET (250 France), F. MURRAY (752 Sweden), X. YAN (840 United States of America), Z. DAVIS (826 United Kingdom of Great Britain and Northern Ireland), E. VAN GASTEL-MOL (528 Netherlands), C. TRESOLDI (380 Italy), Ch. CHU (840 United States of America), N. CAHILL (752 Sweden), V. GIUDICELLI (300 Greece), Boris TICHÝ (203 Czech Republic, belonging to the institution), L. PEDERSEN (208 Denmark), L. FORONI (826 United Kingdom of Great Britain and Northern Ireland), L. BONELLO (380 Italy), A. JANUS (380 Italy), K. SMEDBY (752 Sweden), A. ANAGNOSTOPOULOS (300 Greece), H. MERLE-BERAL (250 France), N. LAOUTARIS (300 Greece), G. JULIUSSON (752 Sweden), P. DI CELLE (380 Italy), Šárka POSPÍŠILOVÁ (203 Czech Republic, belonging to the institution), J. JURLANDER (208 Denmark), Ch. GEISLER (208 Denmark), A. TSAFTARIS (300 Greece), M. LEFRANC (250 France), A. LANGERAK (528 Netherlands), D. OSCIER (826 United Kingdom of Great Britain and Northern Ireland), N. CHIORAZZI (840 United States of America), Ch. BELESSI (300 Greece), F. DAVI (250 France), R. ROSENQUIST (752 Sweden), P. GHIA (380 Italy, guarantor) and K. STAMATOPOULOS (300 Greece)
Edition Blood, Washington, DC, American Society of Hematology, 2012, 0006-4971.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 9.060
RIV identification code RIV/00216224:14740/12:00062998
Organization unit Central European Institute of Technology
Doi http://dx.doi.org/10.1182/blood-2011-11-393694
UT WoS 000305286900021
Keywords in English HEAVY-CHAIN IIA; ANTIGEN RECEPTORS; APOPTOTIC CELLS; IMMUNOGLOBULIN; ANTIBODIES; IG; GENES; REPERTOIRE; SELECTION; SEQUENCE
Tags ok, rivok
Tags International impact, Reviewed
Changed by Changed by: Olga Křížová, učo 56639. Changed: 23/4/2013 08:17.
Abstract
Mounting evidence indicates that grouping of chronic lymphocytic leukemia (CLL) into distinct subsets with stereotyped BCRs is functionally and prognostically relevant. However, several issues need revisiting, including the criteria for identification of BCR stereotypy and its actual frequency as well as the identification of "CLL-biased" features in BCR Ig stereotypes. To this end, we examined 7596 Ig VH (IGHV-IGHD-IGHJ) sequences from 7424 CLL patients, 3 times the size of the largest published series, with an updated version of our purpose-built clustering algorithm. We document that CLL may be subdivided into 2 distinct categories: one with stereotyped and the other with nonstereotyped BCRs, at an approximate ratio of 1:2, and provide evidence suggesting a different ontogeny for these 2 categories. We also show that subset-defining sequence patterns in CLL differ from those underlying BCR stereotypy in other B-cell malignancies. Notably, 19 major subsets contained from 20 to 213 sequences each, collectively accounting for 943 sequences or one-eighth of the cohort. Hence, this compartmentalized examination of VH sequences may pave the way toward a molecular classification of CLL with implications for targeted therapeutic interventions, applicable to a significant number of patients assigned to the same subset.
PrintDisplayed: 24/4/2024 04:04